Neuroblastoma

P3, N=1449, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed

We hypothesize that the GH and TSH deficiency in this case are caused by pituitary damage through binding of [ 177 Lu]Lu-DOTATATE to the somatostatin receptors in the pituitary gland. If [ 177 Lu]Lu-DOTATATE in the future becomes a more upfront treatment we strongly underline screening on pituitary dysfunction after exposure to [ 177 Lu]Lu-DOTATATE in childhood.

This study revealed that certain genes in the adrenal glands and blood affect the occurrence of NB, with immune cells playing a crucial role in the process influenced by blood genes. MR and colocalization prioritize candidate genes/putative therapeutic targets for NB.

P2, N=33, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital

P2, N=20, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026

This study establishes the most comprehensive genomic atlas of Chinese pediatric solid tumors to date, delineating subtype-specific oncogenic variants and chromosomal instability signatures. Our findings advance the understanding of childhood cancer pathogenesis and provide a framework for molecularly guided clinical decision-making.

Its tumor-suppressive functions make it a promising biomarker for cancer diagnosis and prognosis, as well as a candidate for targeted therapies. Despite extensive research, the precise molecular mechanisms underlying MEG3 function remain incompletely understood, underscoring the need for further studies to explore its therapeutic potential in oncology and other diseases.

Although the lesion lacks histopathologic confirmation and a sporadic occurrence cannot be excluded, this observation raises the possibility that germline DNMT3A alterations may predispose to a broader range of tumors than previously recognized. This report underscores the need for continued documentation of unusual tumor presentations in TBRS to further elucidate the biology of DNMT3A-related tumorigenesis.

The infant was discharged on day 44 with improving respiratory status and ongoing outpatient oncology follow-up. This case emphasises the need for rapid recognition of TLS in congenital malignancies and coordinated airway and oncological care.

Future directions include advancing cytokine engineering and combination therapies. Collectively, CAR-NKT cells provide new ideas and new means to break through the difficulties in treating solid tumors and hold the promise of becoming the next generation of cellular immunotherapy.

The ATMP was manufactured and validated in a GMP facility and was obtained from leukapheresis stimulated with zoledronic acid and IL-2, afterward depleted of αβ T lymphocytes using the CliniMACS Prodigy...Furthermore, γδ T lymphocytes and NK cells were cytotoxic against myeloid leukemia or neuroblastoma cells. In conclusion, we implemented a novel ATMP to be shortly translated into clinical practice, which may be used in the post-transplant phase as efficacious immunotherapy in neuroblastoma and leukemic pediatric patients.

P1/2, N=76, Not yet recruiting, National Cancer Institute (NCI)